MT Newswires
Guggenheim Initiates Coverage on Entrada Therapeutics With Buy Rating, $20 Price Target
📊
AI Sentiment
Positive
7/10
as of 02-13-2026 4:00pm EST
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 404.4M | IPO Year: | 2021 |
| Target Price: | $20.00 | AVG Volume (30 days): | 246.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.93 - $13.82 | Next Earning Date: | 03-06-2026 |
| Revenue: | $61,520,000 | Revenue Growth: | -71.42% |
| Revenue Growth (this year): | -84.91% | Revenue Growth (next year): | 21.02% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -129797000.0 | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Chief Financial Officer
Avg Cost/Share
$9.98
Shares
8,910
Total Value
$88,931.60
Owned After
110,026
SEC Form 4
10% Owner
Avg Cost/Share
$9.07
Shares
28,867
Total Value
$261,846.12
Owned After
380,152
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| WENTWORTH KORY JAMES | TRDA | Chief Financial Officer | Nov 21, 2025 | Sell | $9.98 | 8,910 | $88,931.60 | 110,026 | |
| BAKER BROS. ADVISORS LP | TRDA | 10% Owner | Nov 20, 2025 | Buy | $9.07 | 28,867 | $261,846.12 | 380,152 |
TRDA Breaking Stock News: Dive into TRDA Ticker-Specific Updates for Smart Investing
AI Sentiment
Positive
7/10
See how TRDA stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "TRDA Entrada Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.